Albumedix enters evaluation agreement with Novartis

By Maggie Lynch contact

- Last updated on GMT


Related tags: Evaluation, Drug delivery, Novartis

Novartis will use Albumedix’s Veltis drug delivery technology platform to develop several first-in-class therapeutics.

“Our Veltis technology platform offers multiple drug enhancement modalities for the development of more effective, safer and convenient therapeutics,” ​Jonas Skjodt Moller, COO of Albumedix, told us.

The platform, based on Albumedix’s engineered human albumin variant, has attracted interest by pharma and biotech companies looking to further enhance drug candidates, said Moller.

He continued, “Among other functional attributes this includes its validated capability to significantly prolong the duration of action of associated compounds.”

The agreement with Novartis covers the use of Albumedix technology across a range of molecules, targets, and mechanisms. Novartis could not comment further.

“We are very excited to be working with likeminded researchers at Novartis and see this as yet another step towards unlocking the full potential of albumin,”​ Moller said.

Related news

Related products

Flow Cytometry Services

Flow Cytometry Services

Q2 Solutions | 01-Jun-2020 | Data Sheet

We are an established leader in flow cytometry services for clinical trials. Our technologies and solutions meet the growing global demand for enhanced...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Related suppliers

Follow us


View more